Patent Application Attorney Docket No.PC23318A



hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of May, 2004.

Зу	Kelly & Smith.
	(Signature of person mailing) Kelly A. Smith
	(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael J. Munchhof:

APPLICATION NO.: 10/798,198 : Examiner:

FILING DATE: March 10, 2004 : Group Art Unit:

TITLE: NOVEL PYRAZINE COMPOUNDS AS

TRANSFORMING GROWTH FACTOR (TGF)

COMPOUNDS

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>PURSUANT TO 37 C.F.R. § 1.97(b).</u>

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application Attorney Docket No.PC23318A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Christine S. Lee

Attorney for Applicant(s)

Reg. No. 42,788

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 686-2144 01PE

INFOR	XXX	ION DIS	SCLOS	UHEVE	TATION S	AT	TY. DOC	CKET NO	D. PC233	18A :	SERIAL NO	. 10/79	8 <u>,198</u>		
HADEN) Ise se	everal s	heets if	necess	ary)	AP	APPLICANT Michael J. Munchhof								
						FIL	FILING DATE March 10, 2004 GROUP								
						U.S	. PATEN	IT DOC	UMENTS						
EXAMINER INITIAL	AINER DOCUMENT NUMBE					/BER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	us_	3	5	9	9	2	4	4	11/3/70	Polli, et al.	424	19			
	υs	4	0	6	0	9	9	8	11/29/77	Groppenbächer, et	t al. 424	33	1		
	υs	4	1	7	3	6	2	6	11/6/79	Dempski, et al	l. 424	19			
	US	3	1	1	9	7	4	2	1/28/64	Heimlich, et al	l. 167	82			
	US	3	4 .	3	7	3	9	7	1/27/70	Peters, et al.	424	20			
						FORE	IGN PAT	ENT D	OCUMEN.	rs					
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
			00								05.00	00000000			
							· · · · · · · · · · · · · · · · · · ·	r				0000000	YES	NO	
											05.00	00000	YES	NO	
											05.65		YES	NO	
													YES	NO	
													YES	NO	
													YES	NO	
						TS (Inc	cluding A	Author, 1		Pertinent Pag			YES	NO	
		Lapin	ОТН	ER DO	CUMEN				- itle, Date,	Pertinent Pag	es, Etc.)				
		Lapin TGF-	OTH	ER DO	CUMEN bition of Tr	ransform	ing Growth	n Factor (1	Title, Date,		es, Etc.)	ovel Inhibitor			
		Lapin TGF-	OTH	ER DO	CUMEN bition of Tr	ransform	ing Growth	n Factor (1	Title, Date,	Pertinent Pag	es, Etc.)	ovel Inhibitor			
		Lapin TGF-	OTH	ER DO	CUMEN bition of Tr	ransform	ing Growth	n Factor (1	Title, Date,	Pertinent Pag	es, Etc.)	ovel Inhibitor			
EXAMINE	R	Lapin TGF-	OTH	ER DO	CUMEN bition of Tr	ransform	ing Growth	n Factor (1	Title, Date,	Pertinent Paga uced Extracellular I logy, Vol. 62, No.	es, Etc.)	ovel Inhibitor			
	Initial if re	TGF-	OTH g, N.J., et 3 Type I f	ER DO	CUMEN bition of Tr Kinase Act	ransform	ing Growth	n Factor (1 ; Molecula DATE C	GF)-β1-induar Pharmaco	Pertinent Paga uced Extracellular I logy, Vol. 62, No.	es, Etc.) Matrix with a N 1, pp. 58-64 (2)	ovel Inhibitor	of the		

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE